Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan

  • Françoise Kraeber-Bodéré
  • Alain Faivre-Chauvet
  • Caroline Bodet-Milin
  • Amandine Pallardy
  • William A. Wegener
  • Jean-Francois Chatal
  • David M. Goldenberg
Part of the Medical Radiology book series (MEDRAD)


Radioimmunotherapy (RIT) efficacy has been demonstrated in hematology, in particular in B cell non-Hodgkin lymphoma (NHL). RIT can be applied in clinical practice using non-ablative activity of murine anti-CD20 131I-tositumomab and 90Y-ibritumomab tiuxetan. Today, different approaches are explored to improve efficacy of RIT in NHL: myeloablative RIT, RIT as consolidation after chemotherapy, RIT in first-line treatment, fractionated RIT, RIT using other antigen targets or other monoclonal antibody. This chapter reviews current advances in the fractionated radioimmunotherapy, in particular the use of Epratuzumab Tetraxetan, a 90-Y-labeled anti-CD22 antibody in the treatment of non-Hodgkin lymphoma. We present especially the result of a phase I/II, multi center, dose-escalation trial assessing 90Y-hLL2 administered once weekly for 2 or 3 weeks, achieving high rates of durable complete responses with manageable hematological toxicity in NHL relapsing patients.


Follicular Lymphoma Minimal Residual Disease Mantle Cell Lymphoma Complete Response Rate Durable Complete Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Beaumier PL, Venkatesan P, Vanderheyden JL et al (1991) 186-Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res 51:676–681PubMedGoogle Scholar
  2. Bodet-Milin C, Kraeber-Bodéré F, Dupas B et al (2008) Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica 93:390–397PubMedCrossRefGoogle Scholar
  3. Brown JM, Giacca AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58:1408–1416PubMedGoogle Scholar
  4. Buchsbaum DJ, Khazaeli MB, Liu TP, Bright S (1995) Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49. Cancer Res 55:5881–5887Google Scholar
  5. Collins-Burow B, Santos ES (2007) Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Expert Rev Anticancer Ther 7:257–273PubMedCrossRefGoogle Scholar
  6. DeNardo SJ, DeNardo GL, O’Grady LF et al (1987) Radioimmunotherapy of lymphoma with fractionated I-131 Lym-1: phase I/II study [abstract]. J Nucl Med 28:1077Google Scholar
  7. DeNardo GL, DeNardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radioimmunotherapy of B-cell malignancies with 131I- Lym-1. Cancer Res 50:1014–1016Google Scholar
  8. DeNardo GL, DeNardo SJ, Lamborn KR et al (1998a) Low-dose fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm 13:239–254PubMedCrossRefGoogle Scholar
  9. DeNardo GL, DeNardo SJ, Goldstein DS et al (1998b) Maximum tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 16:3246–3256PubMedGoogle Scholar
  10. DeNardo GL, Sclom J, Buchsbaum D et al (2002) Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94:1332–1348PubMedCrossRefGoogle Scholar
  11. Goldenberg DM, Sharkey RM (2006) Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 50:248–264PubMedGoogle Scholar
  12. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24:823–834PubMedCrossRefGoogle Scholar
  13. Gopal AK, Rajendran JG, Gooley TA et al (2007) High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25:1396–1402PubMedCrossRefGoogle Scholar
  14. Griffith MH, Yorke ED, Wessels BW et al (1988) Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 29:1795–1809PubMedGoogle Scholar
  15. Illidge TM, Bayne M, Brown NS et al (2009) Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113:1412–1421PubMedCrossRefGoogle Scholar
  16. Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449PubMedCrossRefGoogle Scholar
  17. Leonard JP, Coleman M, Kostakoglu L et al (2005) Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696–5704PubMedCrossRefGoogle Scholar
  18. Lindén O, Hindorf C, Cavallin-Ståhl E et al (2005) Dose-fractionated radioimmunotherapy in non-Hodgkin’s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 11:5215–5222PubMedCrossRefGoogle Scholar
  19. Liu SY, Eary JF, Petersdorf SH et al (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270–3278PubMedGoogle Scholar
  20. Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195PubMedGoogle Scholar
  21. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM (2008) Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 14:6154–6160PubMedCrossRefGoogle Scholar
  22. Morschhauser F, Illidge T, Huglo D et al (2007) Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood 110:54–58PubMedCrossRefGoogle Scholar
  23. Morschhauser F, Kraeber-Bodere F, Wegener W et al (2010) High rates of durable complete responses with CD22-targeted fractionated radioimmunotherapy: final results of a multicenter, phase I/II study in relapsed/refractory non-Hodgkin’s lymphoma (NHL). J Clin Oncol 28:3709–3716PubMedCrossRefGoogle Scholar
  24. Press OW, Unger JM, Braziel RM et al (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143–4149PubMedCrossRefGoogle Scholar
  25. Schlom J, Molinolo A, Simpson JF et al (1990) Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 82:763–771PubMedCrossRefGoogle Scholar
  26. Sharkey RM, Goldenberg DM (2005) Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46:115S–127SPubMedGoogle Scholar
  27. Sharkey RM, Brenner A, Burton J et al (2003) Radioimmunotherapy of non-Hodgkin’s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000–2018PubMedGoogle Scholar
  28. Sharkey RM, Press OW, Goldenberg DM (2009a) A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 113:3891–3895PubMedCentralPubMedCrossRefGoogle Scholar
  29. Sharkey RM, Karacay H, Johnson CR et al (2009b) Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 50:444–453PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Françoise Kraeber-Bodéré
    • 1
    • 2
  • Alain Faivre-Chauvet
    • 1
    • 2
  • Caroline Bodet-Milin
    • 1
    • 2
  • Amandine Pallardy
    • 2
  • William A. Wegener
    • 3
  • Jean-Francois Chatal
    • 4
  • David M. Goldenberg
    • 5
  1. 1.Cancer Research Center, CRCNA, INSERM UMR892Institut de BiologieNantesFrance
  2. 2.Nuclear Medicine Department, University HospitalICO-René Gauducheau Cancer Center, IRCNANantes-Saint-HerblainFrance
  3. 3.Immunomedics IncMorris PlainsUSA
  4. 4.GIP ArronaxUniversity of NantesNantes-Saint-HerblainFrance
  5. 5.Garden State Cancer CenterCenter for Molecular Medicine and ImmunologyBellevilleUSA

Personalised recommendations